Loading
MRG003 is an experimental antibody-drug conjugate from Lepu Biopharma in phase 3 trials for head and neck squamous cell carcinoma and nasopharyngeal carcinoma, with its target not yet stated publicly.
MRG003 is an antibody-drug conjugate developed by Lepu Biopharma. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05751512 (A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN), in head and neck squamous cell carcinoma and nasopharyngeal carcinoma. The largest, NCT05126719, plans to enrol 238 participants with primary completion was scheduled for 2024-12-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.MRG003's antibody arm binds its target on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MRG003" OR ABSTRACT:"MRG003") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MRG003, not a curated reading list.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma and the tag pipeline.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma and the tag pipeline.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.